About Viatris Inc.
https://www.viatris.comViatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs).
CEO
Scott Andrew Smith
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2003-10-09 | Forward | 3:2 |
| 2003-01-28 | Forward | 3:2 |
ETFs Holding This Stock
Summary
Showing Top 3 of 423
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:140.27M
Value:$1.84B
BLACKROCK INC.
Shares:92.67M
Value:$1.22B
PRICE T ROWE ASSOCIATES INC /MD/
Shares:84.06M
Value:$1.11B
Summary
Showing Top 3 of 1,180
About Viatris Inc.
https://www.viatris.comViatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs).
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $3.76B ▲ | $1.13B ▲ | $-128.2M ▼ | -3.41% ▼ | $-0.11 ▼ | $800.2M ▲ |
| Q2-2025 | $3.58B ▲ | $1.1B ▼ | $-4.6M ▲ | -0.13% ▲ | $-0 ▲ | $577.8M ▲ |
| Q1-2025 | $3.25B ▼ | $4.04B ▲ | $-3.04B ▼ | -93.48% ▼ | $-2.55 ▼ | $-2.32B ▼ |
| Q4-2024 | $3.53B ▼ | $1.39B ▲ | $-516.5M ▼ | -14.64% ▼ | $-0.43 ▼ | $339.9M ▼ |
| Q3-2024 | $3.75B | $1.23B | $94.8M | 2.53% | $0.08 | $905.8M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $1.16B ▲ | $37.92B ▼ | $22.7B ▼ | $15.22B ▼ |
| Q2-2025 | $808.6M ▼ | $38.41B ▼ | $22.84B ▲ | $15.57B ▼ |
| Q1-2025 | $1B ▼ | $38.47B ▼ | $22.82B ▼ | $15.65B ▼ |
| Q4-2024 | $1.09B ▼ | $41.5B ▼ | $22.87B ▼ | $18.64B ▼ |
| Q3-2024 | $2.05B | $44.75B | $24.96B | $19.79B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-128.2M ▼ | $744.9M ▲ | $-98.9M ▼ | $-228.1M ▲ | $435.7M ▲ | $645.2M ▲ |
| Q2-2025 | $-4.6M ▲ | $219.7M ▼ | $-52.5M ▲ | $-362.4M ▲ | $-188.5M ▼ | $165.6M ▼ |
| Q1-2025 | $-3.04B ▼ | $535.5M ▲ | $-65.1M ▲ | $-467M ▲ | $20.2M ▲ | $459.1M ▲ |
| Q4-2024 | $-516.5M ▼ | $482.7M ▼ | $-168.7M ▼ | $-1.42B ▲ | $-1.14B ▼ | $329.3M ▼ |
| Q3-2024 | $94.8M | $826.5M | $1.75B | $-1.64B | $961.6M | $741.1M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Brands | $4.53Bn ▲ | $2.12Bn ▼ | $2.28Bn ▲ | $2.44Bn ▲ |
 Generics | $2.77Bn ▲ | $1.13Bn ▼ | $1.28Bn ▲ | $1.31Bn ▲ |
CEO
Scott Andrew Smith
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2003-10-09 | Forward | 3:2 |
| 2003-01-28 | Forward | 3:2 |
ETFs Holding This Stock
Summary
Showing Top 3 of 423
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:140.27M
Value:$1.84B
BLACKROCK INC.
Shares:92.67M
Value:$1.22B
PRICE T ROWE ASSOCIATES INC /MD/
Shares:84.06M
Value:$1.11B
Summary
Showing Top 3 of 1,180